September 2026—Though it may test the memory of many, there once was a time when HER2 immunohistochemistry was a relatively uncomplicated matter. Back in September 1998, the FDA approved both trastuzumab (Herceptin) and the first companion diagnostic assay, HercepTest, which was used to determine whether patients with metastatic breast cancer could receive the new drug.
September 2026—When Heidi Rehm, PhD, and other researchers examined more than 1.5 million diagnostic sequencing test results from 19 clinical laboratories, they found an astonishing rate of inconclusive reports due to variants of uncertain significance—nearly a third in diagnostic multigene panel testing.
July 2026—This discussion is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on July 21, 2026 with Nick Fingland, PhD, PMP, Senior Director R&D Operations and Science, BD, and Chris Farnsworth, PhD D(ABCC), Section Head of Clinical Chemistry, Professor of Pathology and Immunology, Washington University School of Medicine.
Watch the full conversation:
This roundtable discussion is sponsored by BD.
MAGNUS DECAL redefines tissue processing by integrating automated bone marrow decalcification directly into the processing workflow. Learn More
September 2026—From the CAP’s founding nearly 80 years ago, our organization has had a focus that sets us apart from all other pathology societies: our commitment to laboratory quality. Those of us in the U.S. are very familiar with the CAP accreditation process—which is widely considered the gold standard in laboratory accreditation—as the CAP has deemed status to accredit clinical laboratories under the U.S. Clinical Laboratory Improvement Amendments regulations.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: chemistry/immunoassay analyzers for mid- and high-volume labs
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
December 2022—Hologic has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority. The funding will help bring Hologic’s Panther Fusion SARS-CoV-2/Flu A/B/RSV and Aptima SARS-CoV-2 assays in line with the FDA’s in vitro diagnostic standards and support clinical efforts to obtain claims for nasal samples using the Panther Fusion as well as market authorization for COVID-19 testing of asymptomatic individuals who have reason to be tested. The Aptima SARS-CoV-2 assay received EUA in May 2020, and the CE-marked Panther Fusion SARS-CoV-2/Flu A/B/RSV assay is under development in the United States. The project has been funded with federal funds from the U.S. Department of Health and Human Services, the Administration for Strategic Preparedness and Response, and BARDA.